DMart's Q1FY26 pre-quarter update reveals slower-than-expected revenue growth and margin compression. Competitive pressures, particularly from quick commerce players, could weigh on future growth.
Nuvama reiterated its 'buy' call but raised its target price to ₹1,801, the second highest on the street, after Mirae Asset Securities' ₹1,950
Despite steep premium and short-term earnings dilution, analysts expect Torrent Pharma's acquisition of JB Chemicals to be value accretive in the medium term
Twin wheels of raw material relief and pricing traction power a 26% stock climb
For HMCL, and the two-wheeler sector, there are multiple triggers, which should help it to post a mid-to-high single-digit growth for 2025-26 (FY26)
The launches in the last quarter and a strong outlook has resulted in the stock gaining 21 per over the last month and 42 per cent over three months